| 抗新型冠状病毒肺炎药物靶点的研究进展 |
| |
| 引用本文： | 邓卫宁,王利娜,崔艳丽. 抗新型冠状病毒肺炎药物靶点的研究进展[J]. 现代药物与临床, 2020, 35(3): 401-404 |
| |
| 作者姓名： | 邓卫宁 王利娜 崔艳丽 |
| |
| 作者单位： | 西安医学院附属宝鸡医院 医学检验科, 陕西 宝鸡 721006;天士力控股集团有限公司天士力研究院, 天津 300410;天津药物研究院, 天津 300462 |
| |
| 基金项目： | 江苏省基础研究计划面上资助项目（BK20181209） |
| |
| 摘 要： | 自2019年12月以来,新型冠状病毒(SARS-CoV-2)在国内爆发,并且目前已在日本和韩国等地进入高发态势,该病毒导致的新型冠状病毒肺炎(COVID-19)已造成多人感染并有2500余人死亡,世界卫生组织于2020年1月31日宣布疫情为"国际关注的突发公共卫生事件"。抗新型冠状病毒药物是阻止病毒传播以及在宿主体内复制从而引起肺炎的有力武器。综述了抗COVID-19药物靶点以及相应的药物和候选物的研究进展。
|
| 关 键 词： | 新型冠状病毒肺炎 新型冠状病毒 药物靶点 |
| 收稿时间： | 2020-02-23 |
Research progress on drug targets of anti-corona virus disease 2019 |
| |
| DENG Wei-ning,WANG Li-n,CUI Yan-li. Research progress on drug targets of anti-corona virus disease 2019[J]. Drugs & Clinic, 2020, 35(3): 401-404 |
| |
| Authors: | DENG Wei-ning WANG Li-n CUI Yan-li |
| |
| Affiliation: | Department of Laboratory Medicine, Baoji Affiliated Hospital of Xi''an Medical University, Baoji, Xi''an 721006, China;Tasly Academy, Tasly Holding Group. Co., Ltd., Tianjin 300410, China; Tianjin Institute of Pharmaceutical Research, Tianjin 300462, China |
| |
| Abstract: | The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been in the high incidence since December 2019, and has been in high incidence in Japan and Korea. The corona virus disease 2019 (COVID-19) caused by the virus is likely to cause thousands of people infected and more than 2 500 deaths. On January 31, 2020, the World Health Organization declared the epidemic as Public Health Emergency of International Concern. Anti SARS-CoV-2 drugs are powerful weapons to prevent virus transmission and to cause pneumonia in hosts. Herein, the research progress of the anti SARS-CoV-2 drug targets and related drug candidates were summarized in this papaer. |
| |
| Keywords: | SARS-CoV-2 COVID-19 drug target |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|
